Amazon has eliminated hundreds of jobs in its Pharmacy and One Medical divisions, the company confirmed to CNBC.
“As we continue to make it easier for people to get and stay healthy, we have identified areas where we can reposition resources so we can invest in invention and experiences that have a direct impact on our customers and members of all ages,” Neil Lindsay, who leads Amazon Health Services, wrote in a memo to employees on Tuesday. “Unfortunately, these changes will result in the elimination of a few hundred roles across One Medical and Amazon Pharmacy.”
Business Insider reported earlier on the cuts, which Lindsay said preempted the company’s planned announcement.
Amazon continues to trim its headcount after more than a year of layoffs. The company cut more than 27,000 jobs between late 2022 and mid-2023, as the tech industry downsized alongside soaring inflation and rising interest rates. At the start of this year, Amazon announced cuts in its Prime Video, MGM Studios, Buy with Prime, Twitch and Audible units.
CEO Andy Jassy has been aggressively slashing costs, targeting some of the company’s newer and more unproven bets. A small number of employees were let go in Amazon’s Pharmacy unit last July.
Amazon Chief Financial Officer Brian Olsavsky said on a call with reporters following fourth-quarter earnings last week that the company is still being cautious about headcount expansion. “Where we can find efficiencies and do more with less, we’re going to do that as well,” he said.
Amazon acquired One Medical for roughly $3.9 billion in July 2022, the third-biggest deal in its history, as part of a multiyear effort to grow its presence in health care. In addition to acquiring One Medical, it bought PillPack in 2018 as an entry point into the online pharmacy market, and has launched a virtual health clinic service.
In a separate statement Tuesday, Lindsay said Amazon has seen “very strong momentum and positive customer feedback” across its health-care offerings, and that it will continue to invest in them.
Here’s the full memo from Lindsay:
Hi everyone,
The past year has been incredibly exciting for all of our health care businesses, and we’re seeing tremendous growth for Amazon Pharmacy, One Medical, and Amazon Clinic. We reinvented the Amazon Pharmacy experience throughout 2023 to make it more affordable and convenient for customers to get the prescription medications they need through RxPass, automatic coupons, partnerships, and more. We expanded Amazon Clinic nationwide, and since launch, the marketplace has seen a 96% customer satisfaction rating. And, One Medical continues to grow its membership, benefiting from increased awareness from Amazon, such as the new Prime member benefit, while also focusing on ways to continually improve the care experience for members across One Medical and One Medical Seniors. We remain energized to learn from One Medical’s DNA and scale mechanisms like CI-CARE, alongside Amazon’s Leadership Principles.
As we continue to make it easier for people to get and stay healthy, we have identified areas where we can reposition resources so we can invest in invention and experiences that have a direct impact on our customers and members of all ages. Unfortunately, these changes will result in the elimination of a few hundred roles across One Medical and Amazon Pharmacy.
We are aware these role eliminations are difficult for those impacted, as well as those who have worked alongside them. We will support those who are affected with financial support, benefit continuation, and career assistance to aid in their transition, as well as the opportunity to apply for new roles in the organization.
We typically wait to communicate about these outcomes until we can speak with the people who are directly impacted. However, because one of our teammates leaked this information externally, I wanted you to hear the details directly from me. This is not ideal, and I am sorry if you heard about this externally first. We will communicate with impacted employees tomorrow.
Please know that my leadership team and I will provide guidance on the path forward following these changes. I look forward to working with you to continue helping our customers and members alike get and stay healthy.
Neil
CNBC is now accepting nominations for the 2024 Disruptor 50 list, our annual look at private companies using breakthrough technology to transform industries. Submit your nomination by Friday, Feb. 16., to d50nominations.cnbc.com.
Opendoor shares popped about 10% on Friday after CEO Carrie Wheeler said she’s resigning from the online real estate company, which has seen a surge in recent interest from retail investors.
Pressure began building on Wheeler, who took over the top job in 2022, after the company’s quarterly earnings report earlier this month failed to reassure investors that a turnaround is underway. The stock is up more than sixfold since bottoming out at 51 cents in June, a price that put the company at risk of being delisted from the Nasdaq.
“The last weeks of intense outside interest in Opendoor have come at a time when the company needs to stay focused and charging ahead,” Wheeler wrote in a post on X. “I believe the best thing I can do for Opendoor now is to accelerate my succession plans that I shared with the Board mid-year and make room for new leadership to take the reins.”
Opendoor’s business involves using technology to buy and sell homes, pocketing the gains. In its latest earnings report, Opendoor said it expects to acquire just 1,200 homes in the third quarter, down from 1,757 in the second quarter and 3,504 in the third quarter of 2024. It’s also pulling down marketing spending.
Read more CNBC tech news
Hedge fund manager Eric Jackson, who spearheaded Opendoor’s stock jump in July, celebrated the news and told his new band of followers on X, “Let’s start THINKING BIG AGAIN.” Jackson said last month on X that his firm had taken a stake in the company and was betting it would be a “100-bagger over the next few years.”
Jackson has been a loud voice on X pushing for Wheeler’s departure, and was recently joined by Opendoor co-founder and venture capitalist Keith Rabois, who posted on Aug. 13 that “not a single founder nor executive” who guided the company to its IPO supports Wheeler as CEO.
Opendoor on Friday named technology chief Shrisha Radhakrishna as “president and interim leader” and said a CEO search is underway.
Opendoor went public through a special purpose acquisition company in 2020, riding a SPAC wave supported by low interest rates and Covid-era market euphoria. The soaring inflation and rising interest rates that followed hit all of technology stocks, but had an outsized impact on Opendoor due it its direct exposure to mortgage rates.
The company lost 99% of its value from early 2021 through its trough in June. With Friday’s gains, its market cap stands at about $2.5 billion.
The company forecasted adjusted earnings of $2.11 per this quarter, falling short of the $2.39 per share expected by LSEG. The company projected $6.7 billion in revenue, versus the $7.34 billion estimate.
During an earnings call with analysts, CEO Gary Dickerson said that the current macroeconomic backdrop and trade issues have fueled “increasing uncertainty and lower visibility,” primarily within its China business.
He also said the guidance does not account for pending export license applications and assumes a significant backlog.
Read more CNBC tech news
Applied Materials also cited weakness from leading edge customers and said China clients are easing spending after rapidly ramping up equipment manufacturing in the region.
Bank of America‘s Vivek Arya downgraded shares to a neutral rating and lowered his price target, citing ongoing China and leading-edge headwinds.
“The uncertainty could persist, making it tougher for the stock to outperform despite reasonable valuation,” he wrote. “We suspect the slowdown is more company specific.”
Despite the weak guidance, Applied Materials topped third-quarter earnings and revenue estimates, posting adjusted earnings of $2.48 per share on $7.3 billion in revenue. Net income reached $1.78 billion, or $2.22 a share, versus $1.71 billion, or $2.05 a share, a year ago.
A government intervention in struggling chipmaker Intel is “essential” for the sake of national security, analyst Gil Luria said Friday, following a report that the Trump administration is weighing taking a stake in the company.
“We’re all capitalists,” Luria, head of technology research at D.A. Davidson, said in an interview with CNBC’s “Squawk Box.” “We don’t want government to intervene and own private enterprise, but this is national security.”
Bloomberg reported Thursday that the Trump administration is considering having the U.S. government take a stake in Intel. The news sent Intel shares higher, and the stock climbed again Friday.
Intel previously declined to comment on the report.
Luria said such a deal is needed to revive Intel and reduce the country’s reliance on companies like Samsung and Taiwan Semiconductor to manufacture chips. President Donald Trump has called for more chips and high-end technology to be made in the U.S.
Read more CNBC tech news
How the White House could structure such an intervention is still in question. Bloomberg reported Friday that the administration has discussed using funds from the CHIPS Act.
Intel received $7.9 billion from the Department of Commerce through the CHIPS Act, and it was awarded roughly $3 billion under the CHIPS Act for the Pentagon’s Secure Enclave program.
“Intel has had many opportunities over decades to get it right, and it hasn’t. So we need to intervene,” Luria said. “The government’s going to come in and it’s going to give Intel unfair advantages, and if it’s going to do that, it wants a piece of the business.”
Intel CEO Lip-Bu Tan met with Trump at the White House on Monday after the president called for his resignation based on allegations that he has ties to China.
Luria pointed to OpenAI CEO Sam Altman and Meta CEO Mark Zuckerberg’s comments that the rise of superintelligent AI could be “the next wave of nuclear proliferation,” as evidence that direct intervention by the government is needed.
“We can’t rely on somebody else making shell casings for our nuclear arsenal,” Luria said. “We have to get it right.”